Photo by atikahakhtar from unsplash
This observation is in accordance with a study by Papp et al. The safety profile associated with switching to brodalumab appears favourable and similar to those previously reported. In conclusion,… Click to show full abstract
This observation is in accordance with a study by Papp et al. The safety profile associated with switching to brodalumab appears favourable and similar to those previously reported. In conclusion, the scientific value of this paper is in emphasizing the efficacy and safety of brodalumab in patients who have an inadequate response to ustekinumab, which was previously considered to be one of the most efficacious treatments. This anti-IL-17R is effective for patients who are biologic-naive as much as for patients with some challenging baseline characteristics. This information will be of great interest for the daily practice of dermatologists.
Journal Title: British Journal of Dermatology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!